Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
| ▸ | MLYCD | O95822 | 1/20 | 0.39 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.38 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4965887 | 1.00 | OPRM1 (0.58) | OPRM1OPRD1OPRK1HDAC6HDAC1 | |
| Trifluoroacetic Acid SCHEMBL4964203 | 0.93 | OPRM1 (0.52) | OPRM1OPRD1OPRK1HDAC6HDAC1 | |
| SCHEMBL4968050 | 0.89 | OPRM1 (0.54) | OPRM1OPRD1OPRK1HDAC6HDAC1 | |
| SCHEMBL4964378 | 0.85 | HDAC1 (0.52) | OPRM1OPRD1OPRK1HDAC6HDAC1 | |
| SCHEMBL4966804 | 0.85 | HDAC1 (0.52) | OPRM1OPRD1OPRK1HDAC6HDAC1 | |
| SCHEMBL4968562 | 0.84 | HDAC6 (0.45) | OPRM1OPRD1OPRK1HDAC6HDAC1 | |
| SCHEMBL4965903 | 0.81 | OPRM1 (0.61) | OPRM1OPRD1OPRK1NAMPTRAB9A | |
| SCHEMBL4964153 | 0.80 | OPRM1 (0.56) | OPRM1OPRD1OPRK1HDAC6HDAC1 | |
| SCHEMBL3090215 | 0.79 | HDAC6 (0.71) | OPRM1OPRD1OPRK1HDAC6HDAC1 | |
| Trifluoroacetic Acid SCHEMBL4966249 | 0.78 | HDAC6 (0.40) | OPRM1OPRD1OPRK1HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288543-B2 | For therapy or prophylaxis of obesity and related diseases including eating disorders (bulimia, anorexia nervosa, etc.), diabetes, diabetic complications, diabetic retinopathy, sexual/reproductive disorders, depression, anxiety, epileptic seizure, hypertension, cerebral hemorrhage | ELI LILLY AND COMPANY (US) | 2007-10-30 | — | — | US | claimed |
| US-20070179129-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY | 2007-08-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179129-A1 | Opioid receptor antagonists | OPRK1, OPRM1, OPRL1 | OPRM1 2/4885OPRD1 5/4885OPRK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.